OKYO Pharma
  • Home
  • About
    • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Focus
    • Neuropathic Corneal Pain
    • Rare Corneal Disease
  • Urcosimod
    • Mechanism of Action
    • Preclinical Data
  • NCP Expanded Access
  • Pipeline
    • Overview
    • Urcosimod Development Timeline
  • Investors
    • Investors
    • Share Information
    • Shareholder Services
    • Investor Presentation
    • Analyst Coverage
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press releases
    • In The News
  • Contact
  • Linkedin
  • Twitter
Select Page
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

by Paul | 20th March 2024 | News

-Phase 2 OK-101 efficacy data to be released March 22, 2024- London and New York, NY, March 20, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye...

Recent Posts

  • OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
  • OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
  • OKYO Pharma Announces Purchase of Shares by Director
  • OKYO Pharma Announces Purchase of Shares by Chief Executive Officer
  • OKYO Pharma Announces Purchase of Shares by Chairman

Recent Comments

No comments to show.
OKYO PHARMA

Explore

  • About
  • Disease Focus
  • Urcosimod
  • Pipeline
  • Investors
  • News
  • Contact

Legal

  • Legal
  • Privacy Policy

Follow

  • Follow
  • Follow

© OKYO Pharma, Limited | 2023